---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-012891"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:48:19.331781+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q3 FY2026: Med Tech sales up 19%, raises full-year guidance

## Summary
- Net sales $78.4M (+8.9% pro forma); Med Tech $37.3M (+19%) driven by Auryon, thrombectomy, NanoKnife.
- GAAP net loss $8.1M (-$0.19/shr); adjusted EBITDA $1.8M vs $1.3M prior year.
- Raised FY2026 net sales guidance to $313.5-315.5M; adjusted EBITDA now $10-12M (prev $8-10M).
- Tariff impact $1.3M in Q3; full-year tariff expectation unchanged at $4-6M.
- Cash $37.8M, debt-free; expects Q4 cash flow slightly negative due to $3-5M inventory build for sterilization shutdowns.

## SEC filing metadata
- accession: 0001140361-26-012891
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036126012891/0001140361-26-012891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036126012891/ef20069681_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-012891
- JSON: https://secwatch.observer/filing/0001140361-26-012891.json
- Plain text: https://secwatch.observer/filing/0001140361-26-012891.txt

## Key facts
- Earnings Releases
  ANGIODYNAMICS INC reported third quarter of fiscal year 2026 ended February 28, 2026 results: revenue $78.4 million. Guidance raised.
  - Period: third quarter of fiscal year 2026 ended February 28, 2026
  - Revenue: $78.4 million
  - Guidance: raised
  - Result: reported results
  source text: the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights Quarter Ended February 28, 2026 Pro Forma* YoY Growth Net Sales $78.4 million 8.9% Med Tech Net Sales $37.3 million 19.0% Med Device Net Sales $41.1 million 1.1% • GAAP gross margin of 52.9% • GAAP loss per share of $0.19 • Adjusted loss per share of $0.07
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000114036126012891/0001140361-26-012891-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.